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Abstract
Hypersecretion and chronic phlegm are major symptoms of chronic obstructive pulmonary disease
(COPD) but animal models of COPD with a defined functional hypersecretion have not been
established so far. To identify an animal model of combined morphological signs of airway
inflammation and functional hypersecretion, rats were continuously exposed to different levels of
sulfur dioxide (SO2, 5 ppm, 10 ppm, 20 ppm, 40 ppm, 80 ppm) for 3 (short-term) or 20–25 (long-
term) days. Histology revealed a dose-dependent increase in edema formation and inflammatory
cell infiltration in short-term-exposed animals. The submucosal edema was replaced by fibrosis
after long-term-exposure. The basal secretory activity was only significantly increased in the 20
ppm group. Also, stimulated secretion was significantly increased only after exposure to 20 ppm.
BrdU-assays and AgNOR-analysis demonstrated cellular metaplasia and glandular hypertrophy
rather than hyperplasia as the underlying morphological correlate of the hypersecretion.
In summary, SO2-exposure can lead to characteristic airway remodeling and changes in mucus
secretion in rats. As only long-term exposure to 20 ppm leads to a combination of hypersecretion
and airway inflammation, only this mode of exposure should be used to mimic human COPD.
Concentrations less or higher than 20 ppm or short term exposure do not induce the respiratory
symptom of hypersecretion. The present model may be used to characterize the effects of new
compounds on mucus secretion in the background of experimental COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory airway disease that is characterized
by hypersecretion, cough and inflammatory cell influx
[1,2]. COPD is currently estimated to become the 3rd most
common cause of death in 2020 [3]. The clinical and mor-
phological features of the disease are mediated by
humoral [4] and/or neuronal mediators [5,6] and display
Published: 07 June 2006
Journal of Occupational Medicine and Toxicology 2006, 1:12 doi:10.1186/1745-6673-1-12
Received: 18 May 2005
Accepted: 07 June 2006
This article is available from: http://www.occup-med.com/content/1/1/12
© 2006 Wagner et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
Page 2 of 10
(page number not for citation purposes)
protective first-line responses against inhaled irritants.
However, within chronic exposure to noxious substances
such as tobacco smoke, urban dust, or occupational fac-
tors [7-9], the originally protective mechanisms lead to a
state of chronic phlegm production [10], airway inflam-
mation, and cough, significantly limiting the quality of
life [11]. Under these conditions therapeutic options such
as the efficacy of topically administered drugs become
negatively influenced and respiratory pharmacotransport-
ers may be negatively influenced [12-15].
Next to tobacco smoke exposure, either active or passive,
a number of other environmental factors can be associ-
ated to the development of COPD [16]. Sulfur dioxide
belongs to these factors and its associations to airway dis-
eases have been investigated since the London smogs
[17], which are known to be one of the first characterized
dramatic urban environmental exposures to air pollutants
[18].
The WHO definition of COPD is only based on clinical
criteria. Moreover, there are some morphological meth-
ods such as the Reid index to define histological features
of the disease [19]. However, functional parameters, as
found for the description of allergic obstructive airway
diseases such as allergic bronchial asthma [20], do not
exist. In this respect, in striking contrast to numerous
existing experimental approaches to determine the
inflammation in airway disease [21,22], models to charac-
terize the secretory activity of the airway under the condi-
tions of chronic airway inflammation have not been
established so far. With regard to a situation of a lack in
valid strategies for hypersecretion therapy there is an
urgent need for novel established models to test new ther-
apeutic options [23,24].
Next to chronic chough, that has only been recently
addressed in greater detail by international research
efforts [25-36], also mucus secretion belongs to the few
respiratory symptoms with extremely limited therapeutic
options. A variety of morphological approaches to charac-
terize mucus secretion in the airways have been developed
in the past years [37]. With the first identification of
mucin proteins as the molecular backbone of airway
mucus [38], morphological studies were able to deter-
mine mucin expression in respiratory cells of the upper
[39] and lower airways [40-42]. Also, the pathogenesis of
mucus cell metaplasia was assessed in a murine asthma
model using morphometry [43]. However, these
approaches can be efficiently used to determine the qual-
ity of the secreted mucus but not to exactly assess the
secretory activity under basal or chronic inflammatory
conditions as found in asthma or COPD. Therefore, an
assay needs be established which encompasses a model of
COPD with a defined hypersecretory state of the airways.
The present study aimed to approach this target by com-
bining an animal model of sulfur dioxide-induced lung
lesions with the assessment of airway secretion by basal
and stimulated secretion analysis. Different concentra-
tions of SO2 were used to identify a model which encom-
passes both hypersecretion as defined by elevated basal
secretion and stimulated secretion and morphological
changes similar to those found in human COPD. Using
this approach the first model displaying a clear associa-
tion between hypersecretion as the prominent clinical
symptom of COPD and the pathomorphological features
of the disease should be established.
Methods
Animals
In total, 96 pathogen-free male Sprague-Dawley rats
(Institut für Versuchstierzucht, Hannover, Germany),
weighing 350–400 g were used. The animals were housed
under standard laboratory conditions and fed ad libitum
in accordance to the rules of the animal welfare act and
the local animal committee.
Exposure
For exposure to SO2, 4 animals were transferred to a plexi-
glas chamber with a volume of 57.2 liters. Then, continu-
ous exposure over 24 h to SO2 was started by a controlled
dilution of air and SO2 from a reservoir containing SO2
in a concentration of 1000 mg/m3 using two parallel flow
meters. 12 liter/min of the resulting different SO2-air mix-
tures were then directed through the plexi glass chamber
using a third flow meter. A ventilator inside the chamber
provided constant air movement and the atmosphere was
measured using a hygrometer, thermometer and barome-
ter. SO2 concentrations were measured online (ECS 102-
1, MPSensor Symytems GmbH, Munich, Germany). Con-
trol groups were exposed in a similar plexi glass chamber
to fresh air 12 liter/min instead of SO2 using the same
conditions and measurement of SO2 concentration.
Experimental design
The time-course and dose-relationship of possible
changes in secretory activity was assessed. Therefore, dif-
ferent time and dose schedules were used: short-term (3
d) and long-term (20 – 25 d) periods of permanent expo-
sure to SO2 were chosen to determine secretion under
short and long term exposure (Figure 1).
Also, different doses of SO2 were examined and 6 groups
for each period were assessed: 5 ppm, 10 ppm, 20 ppm,
40 ppm, 80 ppm and control (n = 4 in each experiment).
At the end of the assigned time-period airways were col-
lected for direct measurement of secretory activity. In
addition, tissues were perfusion fixed to study tissue
remodeling by histology.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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Measurement of secretory activity
Airway secretory activity was measured as described in
previously published studies [44-47]. In brief, a midline
collar incision and median sternotomy were performed
and the tracheas were excised and immediately transferred
to 4°C cold M199 culture medium (Serva, Heidelberg,
Germany). Connective tissue was removed and the trach-
eas were opened through a paries membranaceus-inci-
sion. The trachea preparations were then mounted in the
chambers to obtain a mucosal and submucosal side, to
which 7 ml of M-199 medium in Earl's balanced salt solu-
tion (equilibrated with carbogen at 37°C, pH 7.4) was
added. Then, 50 μCi of Na2
35SO4 was placed in the sub-
mucosal side of the preparation and allowed to equili-
brate. The luminal solution was collected every 15 min
and replaced by unlabeled fresh medium. After basal
activity was measured, the stimulated secretion was
assessed using acetylcholine. A luminal stimulation with
1 mmol/l was performed.
The collected probes were stored in cellulose dialysis tub-
ings (cut-off mass 12000–14000 molecular mass) and
dialyzed against distilled water containing unlabeled SO4
to replace non-incorporated Na2
35SO4. To prevent bacte-
rial degradation, sodium azide was added in a concentra-
tion of 10 mg/dl. The levels of radioactivity were then
measured in a liquid scintillation counter with the counts
of labeled macromolecules, which were previously char-
acterized as representing the secretory activity rate of
mucus [48-50].
Histology
Histology was carried out on formalin-fixed lung speci-
men. 5 μm sections were cut from paraffin-embedded tis-
sues and mounted on glass slides. Routine histology was
then carried out as described previously [51] using hema-
toxylin-eosin, alcian blue and the Periodic-Acid-Schiff
(PAS) reaction.
Proliferative activity of glandular and surface epithelial 
cells
In vivo Bromodeoxyuridine (BrdU)-assay
An in vivo BrdU assay (each group n = 5) was performed
as described previously [52]. One hour prior to termina-
tion of exposure, a single injection of 325 μl of 0.17 mM
PBS-buffered BrdU (Boehringer, Mannheim, Germany)
was administered intraperitoneally Sections were proc-
essed as described earlier and endogenous peroxidase
activity inhibited by incubation with 0.5% (v/v) hydrogen
peroxide in methanol for 30 min at room temperature.
Subsequently, slices were digested with 0,004% pepsin
solubilized in 0,1 n HCl and washed in PBS afterwards.
Nuclease-digestion was performed with 10 U/ml EXO III
(Boehringer, Mannheim, Germany) solubilized in 50 mM
Tris-HCl at pH 8,0 as well as 10 mM di-mercapto-ethanol
(Merck, Darmstadt, Germany) and 5% BSA. BrdU was
detected immunohistochemically using a mouse anti
BrdU antibody (Boehringer). This antibody was diluted
1:20 in 50 mM Tris-HCl, 7 mM MgCl2, 50 mM NaCl, 7
mM di-mercapto-ethanol and 1% (W/V) BSA. Incubation
was performed at 37°C for 45 min. Rabbit anti-mouse Ig,
Exposure protocols Figure 1
Exposure protocols.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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diluted at 1:40 in 0,3 mM PBS was used as a link antibody,
and finally mouse-PAP complex was added at 1:200 dilu-
tion. Peroxidase activitiy was detected with 0,01% (v/v)
hydrogen peroxide and 0,05% (w/v) diaminobenzidine
tetrahydrochloride (Dako, Hamburg, Germany). In tissue
sections at least 500 cells were counted per specimen and
tracheal region (superficial epithelium, glandular ducts
and glandular acini).
Argyrophilic nucleolus organizer region (AgNOR)-analysis
To further assess cellular protein synthesis of glandular
and epithelial cells, AgNOR analysis was performed [53].
AgNORs represent the two argyrophilic proteins nucleolin
and nucleophosmin of the nucleolus organizer regions
associated proteins, which are specifically attached to the
nucleolus organizer regions and are directly involved in
cellular protein synthesis. The sections were postfixed for
30 min in a 3:1 ethanol/acetic acid solution at room tem-
perature. A silver colloid soution (1% gelatin and 2% for-
mic acid) was mixedwith 50% siver nitrate in a proportion
of 1:2 to obtain the final working solution for staining of
AgNORs. The silver reaction carried out for 22–24 min in
the dark. The sections were mounted in DPX without
conterstain. The AgNOR analysis was performed by count-
ing the number of AgNOR (black dots) per cell at a mag-
nification of 1000× (each group n = 5 animals).
Analysis of data
The secretory basal and stimulated activity is measured as
counts per minute (cpm). Data are presented as ± S.D. Sta-
tistical analysis was performed using the ANOVA Fried-
man test and the Mann Whitney Wilcoxon U-test.
Results
Secretory activity
To determine the secretory activity in experimental bron-
chitis and to identify a model with proximity to human
conditions concerning hypersecretion and morphological
changes, animals were exposed to five different concentra-
tions of SO2 and significant differences were found
between the exposure and control groups.
Short-term exposure to SO2
Basal secretory activity
After three days of exposure the basal secretion for 5 ppm
(100 ± 26.2 cpm (S.D.)), 10 ppm (103.6 ± 28.5 cpm), and
20 ppm (143.8 ± 38.3 cpm) did not differ significantly
from the control group (85.7 ± 32.9 cpm). After exposure
to 40 and 80 ppm, there was a nonsignificant tendency of
decreased secretory activity (Figure 2).
Stimulated secretory activity
The control group of animals which were only exposed to
air in the chamber exhibited an acetylcholine-stimulated
secretory activity of 224.6 ± 25.7 cpm which differed sig-
nificantly from the basal secretory activity indicating the
reactivity of the glands to parasympathetic stimulation. In
contrast to these differences, no significant changes were
present within the 5 ppm, 10 ppm, 20 ppm, 40 ppm and
80 ppm groups when compared to the control group (Fig-
ure 3).
Long-term exposure to SO2
Basal secretory activity
After 25 days of exposure to SO2 in concentrations of 5
ppm, 10 ppm and 20 ppm, there were no significant dif-
ferences found for 5 ppm and 10 ppm basal secretion. In
contrast, there was a highly significant increase present in
the 20 ppm group with a secretory activity of 309.1 ± 36.9
cpm vs. 99.5 ± 27.1 cpm (control, p < 0.01). In higher con-
centrations, no significant differences were found. In this
respect, in the 80 ppm group which was exposed for 20
days, the basal secretion was 140.1 ± 64.6 cpm (Figure 4).
Stimulated secretory activity
The groups of animals which were exposed for 25 days to
5 ppm or 10 ppm did not differ significantly from the con-
trol group concerning acetylcholine-stimulated secretion.
In contrast, there was a highly significant increase in the
20 ppm group (658.7 ± 99.1 cpm vs. 242.5 ± 73.4 cpm).
Also, values for the 40 ppm group were increased. The
stimulated secretory activity for 80 ppm was recorded on
Secretory basal activity after 3 days of exposure Figure 2
Secretory basal activity after 3 days of exposure. The tra-
cheal secretory basal activity of 6 groups exposed to either 5, 
10, 20, 40, 80 ppm SO2 or fresh air was assessed using a 
modified Ussing Chamber. Results are presented as mean ± 
SD cpm.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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day 20 as further exposure to SO2 was lethal and a value
of 695 ± 337.5 cpm was found (Figure 5).
Airway remodeling
To correlate the hypersecretion as assessed by basal and
acetylcholine-stimulated secretory activity to changes in
the airway structure in order to identify a model which
exhibits both typical morphological features of COPD
and the predominant clinical feature of the disease, hyper-
secretion, the airways of all 12 groups were examined for
airway remodeling and differences were found.
Control group
In control tissues, the surface epithelium was character-
ized by typical ciliated epithelial cells and an intact basal
membrane and very few mucus cells. Mucus glands were
found in the submucosal layer between cartilaginous tis-
sues (Figure 6).
Short-term exposure to SO2
In the surface epithelium, a concentration of 5 ppm did
not influence either the ciliae or shape of the epithelial
cells. From a concentration of 10 ppm single cell necrosis
and an increasing loss of ciliae were found which
increased at higher concentrations. At 80 ppm, the struc-
ture of the surface epithelium is disintegrated with partial
denudation of the basal membrane and inflammatory cell
influx.
Stimulated secretory activity after 25 days of exposure to 5,  10, 20, 40 ppm SO2 or fresh air and 20 days exposure to 80  ppm SO2 Figure 5
Stimulated secretory activity after 25 days of exposure to 5, 
10, 20, 40 ppm SO2 or fresh air and 20 days exposure to 80 
ppm SO2. The acetylcholine-stimulated secretory activity of 
rat tracheas (for each group n = 4) was assessed by the mod-
ified Ussing Chamber technique. Results are presented as 
mean ± SD cpm. ** indicates p < 0.01
Stimulated secretory activity after 3 days of exposure Figure 3
Stimulated secretory activity after 3 days of exposure. The 
acetylcholine-stimulated secretory activity of rats (for each 
group n = 4) exposed to either 5, 10, 20, 40, 80 ppm SO2 or 
fresh air as assessed by the modified Ussing Chamber tech-
nique. Results are presented as mean ± SD cpm.
Secretory basal activity after 25 days of exposure to 5, 10,  20, 40 ppm SO2 or fresh air and 20 days exposure to 80 ppm  SO2 Figure 4
Secretory basal activity after 25 days of exposure to 5, 10, 
20, 40 ppm SO2 or fresh air and 20 days exposure to 80 ppm 
SO2. Results are presented as mean ± SD cpm. ** indicates p 
< 0.01.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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In the submucosal layer, from 5 ppm increasing to higher
concentrations, inflammatory infiltrates and progredient
edema and vascular congestion were found. The infiltra-
tions also reach the submucosal glands.
Long-term exposure to SO2
In contrast to the morphology of short-term exposed air-
ways, after 20 and 25 days of exposure the surface epithe-
lium appeared atypically reorganized with an increased
height of the epithelial cells and shortened/decreased cil-
iae. Also, 20, 40 and 80 ppm exposure led to an increase
of mucus secreting PAS-positive cells (Figure 6).
Proliferative activity of glandular and surface epithelial 
cells
To characterize the proliferative activity of glandular and
surface epithelial cells, an in vivo BrdU-assay was per-
formed. However, in contrast to proliferative activity of
control organs (esophagus), no significant staining for
BrdU was found for glandular structures and surface epi-
thelium and positive staining was only found occasion-
ally (Figure 7).
Also, AgNOR-analysis was performed (Figure 7). Here,
significant differences between the groups were found in
Morphological changes Figure 6
Morphological changes. Representative figures for control animals (A, HE staining; C, Alcian blue) and animals exposed to 80 
ppm SO2 for 20 days (B, HE staining; D, Alcian blue) illustrate airway remodeling with organized, histologically normal epithe-
lium in the control group and structurally altered epithelium after 20 days of exposure. Epithelial cells displayed an increased 
height and a loss of ciliae. Alcian blue staining (C, D) demonstrates an increase of mucus positive cells within the epithelium and 
a loss of ciliae. Original magnification ×400.Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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Proliferative activity of glandular and surface epithelial cells Figure 7
Proliferative activity of glandular and surface epithelial cells. To assess the proliferative activity, an in vivo BrdU-assay and 
AgNOR-analysis were performed. Positive staining indicating BrdU incorporation was only found occasionally in the surface 
epithelium and in glands (A, B). In contrast, AgNOR-analysis demonstrated argyrophilic nucleolar organizer regions (C, D) and 
the AgNOR index (E) revealed significant differences (*, p < 0.05) between exposed and nonexposed groups. Original magnifi-
cation ×400 (×1000, D).Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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the long term-exposed animals. In the glands, the only sig-
nificant differences were present between the 20 ppm
group and the control group (p < 0.05). In the area of the
surface epithelium, all groups differed significantly from
each other. I.e. an index of 1.8 ± 0.1 was found for control
animals and 3.9 ± 0.3 (p < 0.05). For ductal epithelial
cells, significant differences were only found between con-
trol and 10 ppm and 10 and 20 ppm (p < 0.05).
Discussion
Airway mucus protects the respiratory tract against nox-
ious substances und physiological conditions [54,55].
However, under pathological conditions such as COPD,
hypersecretion may negatively influence quality of life
and belongs to the key features of the disease [56].
In contrast to the large number of animal models and
techniques to assess pathophysiological mechanisms
occurring in allergic bronchial asthma [43], only a few
animal models of COPD have been established so far.
These models use exposure to either tobacco smoke [57],
nitrogen dioxide [58] or sulfur dioxide [59] and all pro-
duce features which mimic COPD morphologically with
inflammatory changes and variable emphysema. The
important clinical feature of hypersecretion, which is a
keystone of COPD, has not been assessed directly in ani-
mal models so far and our initial observations led us to
conclude that process parameters and exposure periods
could dramatically affect the production of mucus in
these models. Therefore, hypersecretion may not be an
integrative feature of previously described models of
COPD and thus, the integrity of these models as an
approach to mimic human COPD may be questioned. To
unravel these questions, the present study aimed to estab-
lish a model of COPD which does not only display mor-
phological changes but also a functional hypersecretion as
found in patients with the disease. An assay should be
identified which allows the assessment of the secretory
activity under experimental conditions of COPD.
To functionally assess airway secretory activity, previously
established techniques were applied which allow to meas-
ure both the basal and the metacholine-stimulated tra-
cheal secretion [44-46,48-50].
As exposure to sulfur dioxide has previously been
reported to lead to an experimental form of COPD [59],
the present study aimed to identify a mode of SO2 expo-
sure which encompasses not only morphological features
of COPD, but also a state of hypersecretion and therefore
allows to study the effects of potential new secretion-mod-
ulating compounds in the background of airway inflam-
mation and hypersecretion in future. Five different
concentrations of SO2 were used in two periods. Routine
histopathology revealed signs of bronchitis with increas-
ing concentrations. Within the long-term groups of expo-
sure, signs of fibrotic airway remodeling were found.
Similar changes have also been reported in other studies
using SO2 as noxious compound to evoke experimental
bronchitis [59]. The aim was to correlate morphological
changes in the rat airways to hypersecretion and to find a
protocol of exposure which ensures that both characteris-
tic features of bronchitis and hypersecretion are present
and can be assessed.
Basal and acetylcholine-stimulated secretory activities
were assessed to provide two different scores of mucus
secretion. Hypersecretion was not found in every mode of
SO2 exposure even in the presence of morphological signs
of bronchitis, indicating that previously reported proto-
cols and models may lack a functional hypersecretion and
therefore be biased by not displaying a key feature of
COPD. In this respect, morphological analysis of the three
day exposure groups demonstrated that changes in the air-
way wall structure can be found after this short period of
exposure with the tissues exhibiting signs of acute edema,
loss of ciliar integrity and inflammatory cell influx with
increasing concentrations of SO2. However, basal and
stimulated secretory activity did not reveal any sign of
hypersecretion and instead, in the group of 40 and 80
ppm exposure, tendencies for decreases in the secretion
were found, indicating that short term exposure to a range
of 5 to 80 ppm SO2 can not lead to an adequate model of
bronchitis encompassing both inflammatory and hyper-
secretory changes.
In the groups which were exposed to SO2 for 25 (20)
days, a highly significant increase was present in the basal
secretory state of the 20 ppm group with 309.1 ± 36.9 cpm
vs. 99.5 ± 27.1 cpm in the control group, and also the
stimulated secretion was elevated in this group. These
functional changes were concomitant with morphological
changes of airway remodeling and chronic inflammation
including fibrosis. In contrast, higher concentrations did
not seem to increase basal or stimulated secretion more
significantly and concentrations higher than 80 ppm were
not tolerated by the animals.
To characterize the proliferative activity of glandular and
surface epithelial cells, in vivo BrdU assays and AgNOR-
analysis were performed. However, in contrast to prolifer-
ative activity of control organs (esophagus), no significant
staining for BrdU was found for glandular structures and
surface epithelium. As BrdU is a nucleoside analogue that
is incorporated in the place of thymidine when cells
divide [60], the absence of significant BrdU staining indi-
cates that the observed hypersecretion is not due to an
increased replicative chromosomal activity of glandular
cells. Therefore, an AgNOR-analysis was performed which
is related to rRNA transcriptional activity and cellular pro-Journal of Occupational Medicine and Toxicology 2006, 1:12 http://www.occup-med.com/content/1/1/12
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tein biosynthesis [53] and a significant difference was
found between the 20 ppm group and the control group
but not for higher or lower concentrations.
The dramatic morphologic changes especially of the
superficial epithelium without significant mitotic activity
and without remarkable BRDU incorporation suggests
that a metaplasia with subsequent hypertrophy of the
glandular apparatus rather than hyperplasia as the under-
lying morphological correlate of the hypersecretion. These
findings demonstrate that the exposure of Sprague-Daw-
ley rats over 25 days to a concentration of 20 ppm SO2
leads to a model of experimental COPD with mucus cell
metaplasia and glandular hypertrophy, which encom-
passes both characteristic clinical and morphological fea-
tures of the disease. The possibility to functionally assess
the secretory activity under defined experimental condi-
tions offers the chance to study the effects of potential new
compounds on airway secretion in COPD. Also, the
effects of mediators of inflammation including reactive
oxygen species [61] or neuromediators [62,63] and drug
transport mechanisms [64,65] can be assessed in a setting
of phlegm production and bronchitis.
As it has been shown that the eradication of inflammatory
cells does not automatically lead to an improvement of
clinical symptoms in airway diseases such as allergic
asthma [66], other features of airway diseases such as
hypersecretion or cough are currently focused as a base for
new therapeutic options to improve the quality of life. In
the light of these new strategies [67], models to assess
cough and hypersecretion are required [68]. Therefore,
the presently identified model of 25 day exposure with 20
ppm SO2 may find a broad application. However, SO2 is
a relatively harmful gas and its toxicity may therefore limit
a wide-spread use [69]. Currently, there are a number of
other COPD models available [24]. These include the
exposure to tobacco smoke and future studies on the
secretory state in different protocols of tobacco smoke
concentration and time exposure may offer an alternative
to the presently established protocol.
In conclusion, the present study assessed the influence of
five different concentrations of SO2 in two periods of
exposure. Part of the presently used concentrations which
are much higher than international threshold values did
not lead to any changes. Among the different concentra-
tions it was found that only a 25 days lasting period of
exposure to 20 ppm of SO2 leads to a experimental model
of COPD which does not only show morphological signs
of the disease but also included the predominant clinical
feature of mucus hypersecretion. The model may be used
in future to determine the role of mediators and effects of
new aerosolized compounds on airway secretion in the
background of COPD.
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